Infectious Diseases News and Research

RSS

Calcipotriol drug offers a potential treatment option for fibrotic diseases

Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH).

26 Apr 2013

New research collaboration may help in developing TB vaccine for bovines and humans

Scientists at The University of Nottingham are studying whether harmful bacteria found in cattle could be harnessed to protect livestock from the devastating disease bovine tuberculosis (TB).

26 Apr 2013

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

MDR-TB is tuberculosis, a mycobacterial infection, that has developed resistance to two important and powerful first-line anti-TB drugs, INH and rifampin.

26 Apr 2013

Bill Gates seeks additional $1.5B in donations for polio eradication efforts

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, "is seeking a further $1.5 billion in donations to wipe out polio by 2018 and make it the first infectious disease eradicated since smallpox was wiped from the planet in 1979".

26 Apr 2013

NIAID findings provide structural basis for developing RSV vaccine

An atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody represents a leap toward developing a vaccine for a common-and sometimes very serious-childhood disease.

26 Apr 2013

Cempra reports net loss of $10.3 million in first quarter 2013

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013.

26 Apr 2013

New information on mitigating spread of infection from flu viruses

Pandemic flu continues to threaten public health, especially in the wake of the recent emergence of an H7N9 low pathogenic avian influenza strain in humans.

25 Apr 2013

H7N9 flu virus found to transmit from birds to humans but not person-to-person

Scientists in China have confirmed for the first time that the influenza A H7N9 virus has transmitted from birds—specifically, chicken at a wet poultry market—to humans, according to an Article published Online First in The Lancet.

25 Apr 2013

Directed training facilitates out-of-hours emergency brain scans

An intensive teaching session helps emergency department physicians to reliably interpret head computed tomography scans when a radiologist is not on duty, a study shows.

25 Apr 2013

Donations made, agreements signed to fight polio in advance of Global Vaccine Summit

Hundreds of international health experts and leaders from the public and private sectors are gathered in Abu Dhabi Wednesday for the beginning of the first Global Vaccine Summit, which "is expected to place special emphasis on polio eradication," Gulf News reports (Zaman, 4/23).

25 Apr 2013

Phase I/II data on Baxter's Lyme disease candidate vaccine presented at NFID conference

Baxter International Inc. today announced Phase I/II data evaluating the safety and immunogenicity of its investigational Lyme disease candidate vaccine during the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research in Baltimore, Md.

From Baxter International Inc. 25 Apr 2013

LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its Linking In-Need Communities to Care Initiative.

25 Apr 2013

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Medivir AB today announces that Janssen-Cilag International NV today has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval for simeprevir (TMC435).

25 Apr 2013

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Researchers at the University of Cincinnati have found that targeted screening for populations with a higher estimated prevalence for hepatitis C may be cost-effective.

25 Apr 2013

Research maps risk factors for transmission of animal brucellosis, BTB to humans

A new study at the Institute of Tropical Medicine in Antwerp analyses the impact of animal brucellosis and bovine tuberculosis on animals and people in urban, peri-urban and rural Niger.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

Home-based health education about diseases most effective, finds study

In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found.

24 Apr 2013

Infectious Diseases News and Research

Calcipotriol drug offers a potential treatment option for fibrotic diseases

New research collaboration may help in developing TB vaccine for bovines and humans

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

Bill Gates seeks additional $1.5B in donations for polio eradication efforts

NIAID findings provide structural basis for developing RSV vaccine

Cempra reports net loss of $10.3 million in first quarter 2013

New information on mitigating spread of infection from flu viruses

H7N9 flu virus found to transmit from birds to humans but not person-to-person

Directed training facilitates out-of-hours emergency brain scans

Donations made, agreements signed to fight polio in advance of Global Vaccine Summit

Phase I/II data on Baxter's Lyme disease candidate vaccine presented at NFID conference

LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Research maps risk factors for transmission of animal brucellosis, BTB to humans

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

BD receives FDA approval for second prefilled injectable drug

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Home-based health education about diseases most effective, finds study

eBook: Advancing infectious disease vaccine development eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News